Anti-VEGF treatments have been saving the sight of thousands of people since 2006. In return, however, patients have been making clinical visits as often as monthly for injections. Not only is that a burden on their, and their doctors’, time, but it is very expensive and carries risks. To address the problem, new drug-delivery systems [Read More]
Payments Will Facilitate Beneficiary Access to Argus II in both Inpatient and Outpatient Settings Sylmar, CA- August 15, 2013—Second Sight Medical Products, Inc. today announced that The Argus® II Retinal Prosthesis System (Argus II) has been approved by the Centers for Medicare and Medicaid Services (CMS) beginning October 1, 2013. These payments are designed to support [Read More]
by Dan Roberts March 19, 2008 Over the past several years, scientists have been taking an interest in certain cells within the patient’s own eyes as having the potential to transform into stem-like (progenitor) cells. Called Müller glial cells, they would then migrate to damaged areas of the retina and replace dead cells, restoring vision [Read More]
by Betsy Nisbet November 2001 ANN ARBOR, MI – A paper published electronically by Nature Genetics offers important new insights into the development and differentiation of rod and cone photoreceptors, the light-sensitive cells in the eye’s retina that initiate vision and are essential for clear sight. A team led by Anand Swaroop, Ph.D., professor of [Read More]
